Floatz logo

HC-1119

Prostate Cancer Metastatic

Hinova Pharmaceuticals USA, Inc.Phase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

252 Active assets in the Prostate Cancer Metastatic cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB
Abiraterone Acetate
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

HC-1119 is also rated in:

prostate cancerDormant
B
Indicative ·
60 / 100
View asset →
castration-resistant prostate carcinomaDormant
B
Indicative ·
57 / 100
View asset →
Metastatic Castration Resistant Prostate CancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →